DelMar Pharmaceuticals Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083

December 14, 2016
DelMar Pharmaceuticals, Inc.

DelMar now holds seven allowed United States patents and eight international patents with more than 100 additional patent filings from thirteen patent families representing patent claims covering VAL-083 to 2036 VANCOUVER, British Columbia and MENLO PARK, Calif., Dec. 14, 2016 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on … Continue reading DelMar Pharmaceuticals Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083

Neovasc and Boston Scientific Close US$75 Million Agreement

December 13, 2016
Neovasc Inc.

Vancouver, BC, Canada – December 13, 2016 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVC) today announced the close of its transaction with Boston Scientific Corporation (NYSE: BSX). The two organizations announced a definitive agreement on December 2, 2016 for Boston Scientific to acquire Neovasc’s advanced biologic tissue capabilities and certain manufacturing … Continue reading Neovasc and Boston Scientific Close US$75 Million Agreement

Strong life science representation in top Forty under 40 winners

December 8, 2016

December 8, 2016 – VANCOUVER, BC – LifeSciences BC would like to congratulate Business in Vancouver‘s 2016 Forty under 40. The winners, selected for their noteworthy achievements, highlight BC’s next generation of innovators, influencers and business leaders. Building their legacies early, LifeSciences BC would like to recognize those who work in, and are members of, … Continue reading Strong life science representation in top Forty under 40 winners

Neovasc Provides Update on its Tiara™ Mitral Valve Clinical Program

December 6, 2016

Recent results presented at the ICI Meeting in Israel NASDAQ: NVCNTSX: NVC VANCOUVER, Dec. 6, 2016 /CNW/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVC) today provided an update on the clinical experience with its Tiara™ transcatheter mitral valve. Tiara™ is a novel transcatheter device designed to treat mitral regurgitation (MR), a … Continue reading Neovasc Provides Update on its Tiara™ Mitral Valve Clinical Program

ORTHOPULSE® ANNOUNCES NEXT PHASE OF SALES AND EXPANSION IN NORTH AMERICA

December 5, 2016

VANCOUVER, CANADA / December 2, 2016 – Biolux Research is pleased to announce the expansion of our North American sales force as part of the next phase of OrthoPulse® sales and commercialization. Three new territory managers have joined the Biolux team starting Dec. 1, 2016. Based in California, Kerry Farrell will be the Western territory … Continue reading ORTHOPULSE® ANNOUNCES NEXT PHASE OF SALES AND EXPANSION IN NORTH AMERICA

Neovasc and Boston Scientific Reach US$75 Million Agreement

December 2, 2016

Boston Scientific acquires tissue processing capabilities and takes equity stake in Neovasc NASDAQ: NVCNTSX: NVC VANCOUVER, Dec. 2, 2016 /CNW/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVC) today announced that Boston Scientific Corporation (NYSE: BSX), a global medical technology leader, has agreed to acquire Neovasc’s tissue processing technology and facility for … Continue reading Neovasc and Boston Scientific Reach US$75 Million Agreement

Nova Oculus, StarFish Medical Engage in Manufacturing Partnership

December 1, 2016

Nova Oculus Partners announced a collaborative agreement with StarFish Medical to bring to market a pioneering medical device for the treatment of Age-Related Macular Degeneration. StarFish will be responsible for the development and manufacturing of the Nova Oculus headset, an integral component of the electrotherapeutic medical device Nova Oculus has designed to treat AMD patients. … Continue reading Nova Oculus, StarFish Medical Engage in Manufacturing Partnership

Innovative Medicines Canada Welcomes Pamela Fralick as President

Ottawa, December 1, 2016 – Innovative Medicines Canada is pleased to announce the appointment of Pamela Fralick as its new President, effective immediately. Ms. Fralick comes to Innovative Medicines Canada as a proven healthcare leader, with a wealth of experience advancing critical healthcare initiatives and a deep understanding of public policy and organizational management. “We … Continue reading Innovative Medicines Canada Welcomes Pamela Fralick as President

Aquinox and the University of Southampton Announce Presentation of Abstract at American Society of Hematology Annual Meeting

November 24, 2016

VANCOUVER, British Columbia, Nov. 22, 2016 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced that a collaborative abstract has been accepted for presentation at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition to be … Continue reading Aquinox and the University of Southampton Announce Presentation of Abstract at American Society of Hematology Annual Meeting

Aspect Biosystems Appoints Two New Members to its Board of Directors

November 22, 2016

VANCOUVER, BC, Canada – November 22, 2016 – Aspect Biosystems Ltd., a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering, has announced the appointment of James Hatton and Paul Drohan to its Board of Directors. “We are extremely pleased to welcome James and Paul to our Board of … Continue reading Aspect Biosystems Appoints Two New Members to its Board of Directors